Brachytherapy for Cancers of the Brain

Brachytherapy involves implanting tiny radioactive seeds near to tumor tissue, resulting in a high dosage to the tumor and minimal damage to healthy surrounding tissues and organs. Regardless of where a tumor originates, treating brain tumors… [Learn More…]

Brachytherapy for Breast Cancer with Metastasis to the Brain

Brachytherapy involves implanting tiny radioactive seeds near to tumor tissue, resulting in a high dosage to the tumor and minimal damage to healthy surrounding tissues and organs. Regardless of where a tumor originates, treating brain tumors… [Learn More…]

Chemotherapy Reduces Overall Survival in Children with Low-Grade Glioma

In this retrospective review of children with inoperable intracranial low-grade glioma, it was found that children treated with chemotherapy prior to radiation therapy had a lower 10yr overall survival rate of 85%, compared to 92% for children who… [Learn More…]

Multi-Session Gamma Knife Radiosurgery for Cancers of the Brain

Gamma Knife is a form of external stereostatic radiosurgery that uses 192 smaller beams of radiation to converge on a precise area of the body. With an accuracy of 0.5mm, Gamma Knife has minimal effects on surrounding healthy tissues and can be used… [Learn More…]

Nilotinib for Treatment of Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, CML

Imatinib was one of the first rationally designed drugs to specifically target the BCR-ABL fusion gene found in CML. Unfortunately, many patients eventually develop resistance to Imatinib. Nilotinib is a new drug designed to treat… [Learn More…]

Adjuvant Endocrine Therapy plus Zoledronic Acid in Premenopausal Women

Zoledronic acid is a drug used to treat bone metastasis. Addition of Zoledronic acid to either tamoxifen or anastrozole increased disease-free survival by 36% compared with either tamoxifen or anastrozole alone. At a median follow-up of just under… [Learn More…]

Vemurafenib (PLX4032) for Metastatic Melanoma

PLX4032 is a next generation oral BRAF inhibitor for the treatment of melanoma. Data from the BRIM 2 clinical trial of previously untreated melanoma patients showed that  53% of the patients experienced tumor shrinkage compared with only 5% for… [Learn More…]

Vismodegib for Basal Cell Carcinoma

Vismodegib is an inhibitor of the hedgehog signaling pathway, a pathway involved in regulating adult stem cells that is over-active in more than 90% of basal cell carcinomas. This phase II clinical trial resulted in an increased progression free… [Learn More…]

Amazing Results From ICT-107 Glioblastoma Clinical Trial

ICT-107 is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma and is showing an 80.2% overall survival at 2yrs and 55% overall survival at 3yrs, with 38% of patients disease free at 3yrs…compared to a… [Learn More…]

DCVax: Slowing the Progression of Metastatic Prostate Cancer.

Prostate cancer patients whom experience rising PSA levels while on hormone treatment typically progress to metastatic disease on average in about 28-36 weeks. DCVax is a vaccine made from a patient’s own dendritic cells and loaded with a form of… [Learn More…]